Tvardi Therapeutics initiated with a Buy at BTIG

BTIG initiated coverage of Tvardi Therapeutics (TVRD) with a Buy rating and $55 price target Tvardi is the “presumptive first mover” in the development of STAT3 inhibitors for fibrotic disease, the analyst tells investors in a research note. The fir, says STAT3 is a “highly validated and well-characterized” target but historically has not been druggable due to its essential roles in cell respiration. BTIG believes the company’s TTI-101 is well positioned to emerge as a breakthrough therapy in fibrosis. It sees the stock undervalued ahead of Phase 2 idiopathic pulmonary fibrosis data in the second half of 2025.